Adeka (4401) Q1 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2027 earnings summary
18 Sep, 2026Executive summary
Net sales rose 15.2% year-over-year to ¥117.0 billion in Q1 FY2026, with operating profit up 42.7% to ¥15.6 billion and profit attributable to owners up 47.8% to ¥10.7 billion.
Growth was driven by strong demand in chemicals, semiconductor materials, and life science, while food products saw increased sales but decreased profit due to higher raw material costs.
Overseas sales ratio increased to 55.9%, with overseas sales up ¥9.9 billion year-over-year.
Full-year earnings and dividend forecasts were revised upward due to favorable business conditions and strong Q1 results.
Accelerated investments in growth domains and supply systems to meet future demand.
Financial highlights
Q1 net sales reached ¥117.0 billion, up ¥15.4 billion year-over-year.
Operating profit rose ¥4.6 billion to ¥15.6 billion; ordinary profit up 50.2% to ¥16.6 billion.
Quarterly profit increased ¥3.4 billion to ¥10.7 billion; EPS up ¥38.9 to ¥110.1.
Comprehensive income nearly doubled to ¥20,357 million from ¥10,227 million a year earlier.
Gross profit margin improved, with gross profit at ¥35,429 million versus ¥28,950 million last year.
Outlook and guidance
FY2026 forecast: ¥462.0 billion net sales, ¥50.0 billion operating and ordinary profit, ¥32.0 billion profit attributable to owners.
Forecasts revised upward from May: net sales +¥9.0 billion, operating profit +¥3.2 billion.
Annual dividend forecast raised to ¥132.00 per share, including a commemorative dividend; interim dividend at ¥66 per share.
Dividend payout ratio maintained at 40%+; 18 consecutive years without a dividend reduction.
Latest events from Adeka
- Q1 earnings fell on volume weakness; FY profit targets stayed intact.document-source184401
Q1 2024 - Record FY2023 profits set the stage for ADX 2026 growth and JPY 75 billion in CapEx.4401
Q4 2024 - Pricing and FX cushioned volume-led pressure as FY2023 guidance remained unchanged.4401
Q3 2024 - Record FY2025 results; FY2026 forecasts further growth but exclude Middle East impacts.4401
Q4 2026 - H1 growth lifted FY2024 guidance and dividends, led by Chemicals.4401
Q2 2025 - Nine-month profit rose 25.1%, led by Chemicals, as semiconductor investment advanced.4401
Q3 2025 - Record FY2024 results, with FY2025 growth forecast amid tariff and cost risks.4401
Q4 2025 - Profit and sales rose, led by Life Science, with stable outlook and higher dividend forecast.4401
Q1 2026 - Profit rose on strong Life Science and Environmental Materials, offsetting Chemicals weakness.4401
Q3 2026